Literature DB >> 22394600

Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features.

Abdel Kareem Azab1, Jinsong Hu, Phong Quang, Feda Azab, Costas Pitsillides, Rana Awwad, Brian Thompson, Patricia Maiso, Jessica D Sun, Charles P Hart, Aldo M Roccaro, Antonio Sacco, Hai T Ngo, Charles P Lin, Andrew L Kung, Ruben D Carrasco, Karin Vanderkerken, Irene M Ghobrial.   

Abstract

The spread of multiple myeloma (MM) involves (re)circulation into the peripheral blood and (re)entrance or homing of MM cells into new sites of the BM. Hypoxia in solid tumors was shown to promote metastasis through activation of proteins involved in the epithelial-mesenchymal transition (EMT) process. We hypothesized that MM-associated hypoxic conditions activate EMT-related proteins and promote metastasis of MM cells. In the present study, we have shown that hypoxia activates EMT-related machinery in MM cells, decreases the expression of E-cadherin, and, consequently, decreases the adhesion of MM cells to the BM and enhances egress of MM cells to the circulation. In parallel, hypoxia increased the expression of CXCR4, consequently increasing the migration and homing of circulating MM cells to new BM niches. Further studies to manipulate hypoxia to regulate tumor dissemination as a therapeutic strategy are warranted.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22394600      PMCID: PMC3382938          DOI: 10.1182/blood-2011-09-380410

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.

Authors:  Jinsong Hu; Damian R Handisides; Els Van Valckenborgh; Hendrik De Raeve; Eline Menu; Isabelle Vande Broek; Qian Liu; Jessica D Sun; Ben Van Camp; Charles P Hart; Karin Vanderkerken
Journal:  Blood       Date:  2010-06-07       Impact factor: 22.113

Review 2.  Snail family regulation and epithelial mesenchymal transitions in breast cancer progression.

Authors:  Antonio Garcia de Herreros; Sandra Peiró; Mayssaa Nassour; Pierre Savagner
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-05-09       Impact factor: 2.673

3.  Negative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesis.

Authors:  Peter Horak; Andrew R Crawford; Douangsone D Vadysirisack; Zachary M Nash; M Phillip DeYoung; Dennis Sgroi; Leif W Ellisen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-22       Impact factor: 11.205

4.  Transcriptional regulation and functional implication of the grass carp CITED1 (gcCITED1) in the negative regulation of HIF-1.

Authors:  Patrick Kwok Shing Ng; Richard Man Kit Yu; Theresa Fuk Ning Kwong; Minnie Man Lai Wong; Richard Yuen Chong Kong
Journal:  Int J Biochem Cell Biol       Date:  2010-06-12       Impact factor: 5.085

5.  Hypoxia-inducible factor-1 alpha, in association with TWIST2 and SNIP1, is a critical prognostic factor in patients with tongue squamous cell carcinoma.

Authors:  Xinhua Liang; Min Zheng; Jian Jiang; Guiquan Zhu; Jing Yang; Yaling Tang
Journal:  Oral Oncol       Date:  2010-12-16       Impact factor: 5.337

6.  Epithelial-mesenchymal transition of rat peritoneal mesothelial cells via Rhoa/Rock pathway.

Authors:  Hao Zhang; Xiaoxian Liu; Yan Liu; Bin Yi; Xueqing Yu
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-11-25       Impact factor: 2.416

7.  Feedback regulators of hypoxia-inducible factors and their role in cancer biology.

Authors:  Anne-Theres Henze; Till Acker
Journal:  Cell Cycle       Date:  2010-07-30       Impact factor: 4.534

8.  mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways.

Authors:  Pat Gulhati; Kanika A Bowen; Jianyu Liu; Payton D Stevens; Piotr G Rychahou; Min Chen; Eun Y Lee; Heidi L Weiss; Kathleen L O'Connor; Tianyan Gao; B Mark Evers
Journal:  Cancer Res       Date:  2011-03-23       Impact factor: 12.701

9.  Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.

Authors:  Sally K Martin; Peter Diamond; Sharon A Williams; Luen Bik To; Daniel J Peet; Nobutaka Fujii; Stan Gronthos; Adrian L Harris; Andrew C W Zannettino
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

10.  Hypoxia suppression of Bim and Bmf blocks anoikis and luminal clearing during mammary morphogenesis.

Authors:  Kelly A Whelan; Sarah A Caldwell; Kristina S Shahriari; S RaElle Jackson; Lisa D Franchetti; Gregg J Johannes; Mauricio J Reginato
Journal:  Mol Biol Cell       Date:  2010-09-22       Impact factor: 4.138

View more
  145 in total

1.  Myeloma as a model for the process of metastasis: implications for therapy.

Authors:  Irene M Ghobrial
Journal:  Blood       Date:  2012-04-24       Impact factor: 22.113

Review 2.  Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia.

Authors:  Muhammad Zaeem Noman; Meriem Hasmim; Yosra Messai; Stéphane Terry; Claudine Kieda; Bassam Janji; Salem Chouaib
Journal:  Am J Physiol Cell Physiol       Date:  2015-08-26       Impact factor: 4.249

Review 3.  The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Authors:  Irene M Ghobrial; Alexandre Detappe; Kenneth C Anderson; David P Steensma
Journal:  Nat Rev Clin Oncol       Date:  2018-01-09       Impact factor: 66.675

Review 4.  Pathogenesis beyond the cancer clone(s) in multiple myeloma.

Authors:  Giada Bianchi; Nikhil C Munshi
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

5.  Direct measurement of hypoxia in a xenograft multiple myeloma model by optical-resolution photoacoustic microscopy.

Authors:  Toru Imai; Barbara Muz; Cheng-Hung Yeh; Junjie Yao; Ruiying Zhang; Abdel Kareem Azab; Lihong Wang
Journal:  Cancer Biol Ther       Date:  2017-01-03       Impact factor: 4.742

6.  Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.

Authors:  Talha Badar; Damian R Handisides; Juliana M Benito; Mary Ann Richie; Gautam Borthakur; Elias Jabbour; Karine Harutyunyan; Sergej Konoplev; Stefan Faderl; Stew Kroll; Michael Andreeff; Tillman Pearce; Hagop M Kantarjian; Jorge E Cortes; Deborah A Thomas; Marina Konopleva
Journal:  Am J Hematol       Date:  2016-06-25       Impact factor: 10.047

7.  Promising therapies in multiple myeloma.

Authors:  Giada Bianchi; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2015-06-01       Impact factor: 22.113

8.  CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation.

Authors:  Aldo M Roccaro; Yuji Mishima; Antonio Sacco; Michele Moschetta; Yu-Tzu Tai; Jiantao Shi; Yong Zhang; Michaela R Reagan; Daisy Huynh; Yawara Kawano; Ilyas Sahin; Marco Chiarini; Salomon Manier; Michele Cea; Yosra Aljawai; Siobhan Glavey; Elizabeth Morgan; Chin Pan; Franziska Michor; Pina Cardarelli; Michelle Kuhne; Irene M Ghobrial
Journal:  Cell Rep       Date:  2015-07-16       Impact factor: 9.423

9.  Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance.

Authors:  Barbara Muz; Hubert D Kusdono; Feda Azab; Pilar de la Puente; Cinzia Federico; Mark Fiala; Ravi Vij; Noha N Salama; Abdel Kareem Azab
Journal:  Leuk Lymphoma       Date:  2017-05-16

10.  Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment.

Authors:  Linhua Jin; Yoko Tabe; Hongbo Lu; Gautam Borthakur; Takashi Miida; Hagop Kantarjian; Michael Andreeff; Marina Konopleva
Journal:  Cancer Lett       Date:  2012-10-02       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.